Skip to main content

Table 4 Predictors of persistence of protective antibody levels for both 23F and 6B 1.5 years after pneumococcal vaccination by using 7-valent conjugate vaccine in patients with rheumatoid arthritis and spondyloarthropathy

From: Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different antirheumatic drugs

Univariate logistic regression analysis
  RA
P value; OR (95% CI)
Spondyloarthropathy
P value; OR, 95% CI
Age ≥65 years (yes/no) P = 0.144; OR 0.59 (0.29-1.2) P = 0.012; OR 0.24 (0.08-0.74)
Gender (male/female) P = 0.727; OR 0.86 (0.37-2.0) P = 0.120; OR 1.72 (0.07-3.40)
Disease duration (years) P = 0.011; OR 0.96 (0.93-0.99) P = 0.895; OR 1.0 (0.97-1.03)
DAS at vaccination (0-6.5) P = 0.684; OR 0.94 (0.68-1.28) P = 0.014; OR 0.70 (0.51-0.93)
HAQ at vaccination (0-3) P = 0.020; OR 0.54 (0.32-0.91) P = 0.043; OR 0.48 (0.24-0.98)
Ongoing MTX (yes/no) P = 0.807; OR 0.92 (0.45-1.9) P = 0.078; OR 0.53 (0.26-1.07)
Ongoing anti-TNF (yes/no) P = 0.066; OR 0.53 (0.27-1.04) P = 0.086; OR 0.51 (0.24-1.1)
Ongoing prednisolone (yes/no) P = 0.259; OR 0.64 (0.29-1.40) P = 0.390; OR 0.62 (0.21-1.84)
Positive antibody response for both 6B and 23F at 4 to 6 weeks P = 0.180; OR 1.70 (0.78-3.71) P = 0.630; OR 1.19 (0.59-2.36)
Protective prevaccination antibody levels for both 23F and 6B (yes/no) P < 0.001; OR 12.1 (5.38-27.4) P < 001; OR 14.6 (5.83-36.4)
Multivariate logistic regression analysis
Age ≥65 years (yes/no) P = 0.188; OR 0.59 (0.26-1.30) P = 0.017; OR 0.22 (0.06-0.76)
Gender (male/female) P = 0.480; OR 0.70 (0.26-1.88) P = 0.637; OR 1.24 (0.51-2.97)
Disease duration (years) P = 0.214; OR 0.98 (0.94-1.01) P = 0.873; OR 1.01 (0.97-1.04)
HAQ at vaccination (0-3) P = 0.139; OR 0.62 (0.32-1.17) P = 0.291; OR 0.63 (0.27-1.49)
Ongoing MTX (yes/no) P = 0.065; OR 0.39 (0.14-1.06) P = 0.882; OR 0.94 (0.39-2.27)
Ongoing anti-TNF (yes/no) P = 0.024; OR 0.34 (0.13-0.87) P = 0.195; OR 0.54 (0.21-1.37)
Positive antibody response for both 6B and 23F at 4-6 weeks P = 0.388; OR 1.45 (0.62-3.40) P = 0.916; OR 1.04 (0.49-2.23)
  1. Adjusted for age older than 65 years, gender, disease duration, HAQ, ongoing MTX, ongoing anti-TNF, and positive antibody response for both serotypes tested. MTX, methotrexate; HAQ, health-assessment questionnaire.